Status:
UNKNOWN
LGI1-antibody Patients Follow-up
Lead Sponsor:
Hospices Civils de Lyon
Conditions:
Anti-LGI1 Encephalitis
Eligibility:
All Genders
18+ years
Brief Summary
Autoimmune encephalitis involve autoantibodies targeting central nervous system, and particularly the synapse or its structure like for LGI1 protein. Anti-LGI1 encephalitis is revealed by an inflammat...
Eligibility Criteria
Inclusion
- Age \> 18 years
- Diagnosis of anti-LGI1 encephalitis based on sera or CSF samples in the National Reference Center of autoimmune encephalitis from 2011/06 to 2019 july 1st.
- Clinical follow-up in France
Exclusion
- Anti-LGI1 antibody associated with another encephalitis antibody
- Foreign follow-up
Key Trial Info
Start Date :
October 30 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 30 2020
Estimated Enrollment :
192 Patients enrolled
Trial Details
Trial ID
NCT04106765
Start Date
October 30 2019
End Date
December 30 2020
Last Update
October 15 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre de référence des syndromes neurologiques paranéoplasiques et encéphalites auto-immunes
Lyon, France